RLT
RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
Oliver Sartor, MDRLT | November 21, 2024
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
View More
Brian Rini, MD, FASCORLT | October 29, 2024
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
Brian Rini, MD, FASCORLT | October 29, 2024
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
Brian Rini, MD, FASCORLT | October 29, 2024
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
Brian Rini, MD, FASCORLT | October 25, 2024
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
Brian Rini, MD, FASCORLT | October 24, 2024
The first part of five segments from the Uromigos Live 2024 session on radioligands.
Emily MenendezRLT | October 9, 2024
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
Brian Rini, MD, FASCORLT | October 3, 2024
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
Christopher Wallis, MD, PhD, FRCSCCRPC | October 1, 2024
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
Karine Tawagi, MDCRPC | October 3, 2024
SPLASH continues to show benefit for PSMA RLT in mCRPC and adds to this consideration in the pre-chemotherapy setting.
Katy MarshallRLT | October 17, 2024
177Lu-PSMA-617 is a PSMA-targeted radioligand therapy in patients with mCRPC.
Emily MenendezRLT | October 17, 2024
Multiple cycles of AcPSMA can cause side effects including salivary gland toxicity and xerostomia.
Vishnu MurthyCRPC | July 8, 2024
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Oliver Sartor, MDRLT | June 18, 2024
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Geoffrey Johnson, MD, PhDRLT | June 17, 2024
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Emily MenendezProstate Cancer | June 13, 2024
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Emily MenendezCRPC | June 13, 2024
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
Advertisement
Advertisement
Advertisement